The actual pandemic infection related to SARS-CoV2 results in viral pneumonitis (COVID-19), that may, in the more severe cases, lead the patients to the intensive care unit (ICU). The more frequent presentation is acute respiratory distress syndrome (ARDS). To penetrate cells, SARS-CoV2 uses Angioconvertase type 2 (ACE2) as a cellular entry receptor. ACE2 belong to the renin-angiotensin-aldosteron system (SRAA), and ACE2 levels are directly modified when SRAA inhibitors are administred to patients, and ACE2 level increases particularely with Angiotensin II Receptor blockers (ARA2) use. The aim of our study is to determine ACE2 level and activity in patients with SARSCoV2 infection admitted to the intensive care unit (ICU). COVID ARA2 is a propsective cohort of patient with blood sampling at the day of admission, day 3 and day 7.
The actual pandemic infection related to SARS-CoV2 results in viral pneumonitis (COVID-19),
that may, in the more severe cases, lead the patients to the intensive care unit (ICU). The
more frequent presentation is acute respiratory distress syndrome (ARDS).
To penetrate cells, SARS-CoV2 uses Angioconvertase type 2 (ACE2) as a cellular entry
receptor.
ACE2 belong to the renin-angiotensin-aldosteron system (SRAA), and ACE2 levels are directly
modified when SRAA inhibitors are administred to patients, and ACE2 level increases
particularely with Angiotensin II Receptor Blockers (ARA2) use.
The aim of our study is to determine ACE2 level and activity in patients with SARSCoV2
infection admitted to the intensive care unit (ICU).
COVID ARA2 is a propsective cohort of patient with blood sampling at the day of admission,
day 3 and day 7.
Biological: blood sampling
blood sampling at the day of admission, day 3 and day 7
Inclusion Criteria:
- admission to the intensive care unit,
- with a proven COVID infection, responsible for acute respiratory failure
- agree with participation to the study.
Exclusion Criteria:
- aged under 18
- under legal protection
- pregnant or breastfeeding
University Hospital Angers
Angers, France
Investigator: Julien Demiselle, M.D.
Contact: 33 (0)241355865
julien.demiselle@chu-angers.fr
Pierre Asfar, MD, PhD
+33241355865
piasfar@chu-angers.fr
Julien Demiselle, MD
+33241355865
julien.demiselle@chu-angers.fr
Pierre Asfar, MD, PhD, Principal Investigator
CHU Angers, service de médecine intensive réanimation